Possessing extensive executive experience in accounting and finance, Peter Culpepper serves as the chief operating officer and chief financial officer of Provectus Biopharmaceuticals. Recently, Peter Culpepper’s company announced the receipt of a United States patent that will extend protection to the manufacturing process of PV-10, a trial-stage drug that has been patented since 2013. The new patent prohibits the use of any alternative raw materials to create the same active ingredient found in PV-10.
With coverage until at least 2031, the new patent keeps the company’s intellectual property safe as it tests its proprietary drug through clinical trials, including a pivotal phase 3 trial examining the efficacy of PV-10 in the treatment of melanoma.
Co-inventors on the patent include scientists from Cambrex Charles City, a subsidiary of Cambrex Corporation. These scientists partnered with Provectus to develop the unique manufacturing process that makes it possible to produce the active ingredient in PV-10, and their inclusion on the patent is a small recognition of the contribution that they have made.
An experienced accounting and finance executive, Peter Culpepper is the chief financial officer and chief operating officer of Provectus Biopharmaceuticals. Earlier this year, Peter Culpepper’s company announced that it would start a phase 1 study of the efficacy of PV-10 in the treatment of neuroendocrine tumors that have metastasized in the liver. The trial will involve 12 patients and will take place at the Queen Elizabeth Hospital in South Australia.
With the phase 1 study, the researchers hope to test the safety and tolerability, as well as the effectiveness, of PV-10 chemoablation. The study will run for two years, with interim data taken after a year. Participants are divided into two successive cohorts. The first will receive PV-10 treatment in a single liver tumor, while the second will receive treatment in multiple tumors.
To judge effectiveness of the treatment, research will assess the objective response rate of both treated and untreated tumors, as well as any changes in tumor biomarkers that might occur. The key biomarkers include 5-hydroxyindole acetic acid, chromogranin A, and somatostatin receptor expression.
Peter Culpepper is the CFO and COO of Provectus Biopharmaceuticals. Aside from leading the company into developing therapies to destroy the deadliest cancers, Peter Culpepper is involved with the American Cancer Society which recently published an article on the development of a revolutionary colon cancer screening test.
Colonoscopy is one way for doctors to find colon cancer. The invasive procedure has been known to cause jitters in many, even more so when considering the bowel clearing preparations that go with it.
Developments in testing for colon cancer have led to the innovation of a new non-intrusive test for screening. The test, known as a stool DNA test, uses the patient’s stool to look for specific gene changes associated with cancer cells.
Approved by the FDA in 2014, the test has patients collecting samples of their stools and mailing them to labs. The stool is then checked for two things indicative of cancer: changes in DNA and traces of blood.
No special diet is needed for the test, neither are laxatives and enemas for bowel preparation.
The test is only available for patients with no history of colon cancer, precancerous polyps, or certain colon problems.
Peter Culpepper was a management consultant at Felix Culpepper International before joining Provectus Biopharmaceuticals in 2004 as corporate officer/CFO. Under Peter Culpepper’s stewardship, Provectus Biopharmaceuticals received a patent for the manufacturing of PV-10’s active ingredient.
A company specializing in the development of oncology and dermatology therapies, Provectus Biopharmaceuticals was successful in getting a U.S Patent and Trademark Office patent covering its use of a unique element in the manufacture of the active ingredient API for PV-10. The unique ingredient is being used in all clinical trials for PV-10, which is a proposed therapy for metastatic melanoma.
The patent granted to Provectus Biopharmaceuticals, Patent No. 9,273,022, is valid until 2031. It guarantees protection for the commercial manufacture of PV-10.
A critical part of any new drug is the Chemistry, Manufacturing, and Controls. This is where scientists work to enable the manufacturing of active ingredients in drugs, leading to ground-breaking techniques that can be patented.
Provectus Biopharmaceuticals worked closely with Cambrex Charles City, Inc., to bring the patent application process to fruition. Cambrex Charles City provides services that improve both the initial development and later commercialization of therapeutics.
American Institute of CPAs
Certified Public Accountant (CPA) Peter Culpepper has had a long career in finance. The chief financial officer of Provectus Biopharmaceuticals, Peter Culpepper is a member of the American Institute of CPAs (AICPA).
Every year, the AICPA Employee Benefits Plans Conference is organized to address the issues affecting the practice of auditing and tax compliance. This year’s conference will be held on May 10-12, 2016, at the ARIA Resort & Casino in Las Vegas, Nevada. The conference will offer insights into how companies can approach audit and tax compliance to meet even the highest level of scrutiny.
Speakers at the conference will include AICPA senior vice president of public practice Susan Coffey, Spaulding Companies Corporation president Tommy Spaulding, and PricewaterhouseCoopers senior strategic advisor Hon. David Walker. Every session will be customized by skill level and accountancy proficiency. CPAs, tax professionals, auditors, and financial reporting consultants are invited to attend the AICPA Employee Benefits Plans Conference.
Pete Culpepper is a senior financial executive and current chief financial officer and chief operating officer of Provectus Pharmaceuticals. Peter Culpepper is a member of Financial Executives International.
Headquartered in Morristown, New Jersey, Financial Executives International (FEI) has more than 80 chapters in the United States, Canada, and Japan. FEI connects senior-level financial executives and works to define the profession, transfer knowledge, and collaborate with government to improve the general economy. Today, FEI offers conferences, meetings, and online forums where members can exchange best practices and enrich their expertise.
A key initiative of FEI is the Financial Executive Research Foundation (FERF), a separate 501(c)(3) organization founded in 1944. Since its inception, FERF has performed impartial, independent research on important financial and strategic management topics. FERF frequently partners with other organizations to conduct industry research and provide professional education programs.
As the member of a company’s senior management team who is responsible for overseeing all aspects of its financial standings, a Chief Financial Officer (CFO) is a highly important individual in any organization. Essentially, the CFO’s position involves monitoring all inflow and outflow of cash. The CFO handles credit, prepares budgets, oversees tax issues, and maintains the balance between revenues and expenditures. He or she is also responsible for developing a company’s financial strategy for the future.
The CFO is at the head of many of a company’s essential functions, and consequently, is open to a wide range of liability issues such as fraud or embezzlement. To ensure the ability to manage all required tasks properly, the CFO must possess a solid background in business, a great deal of training, and often, an advanced academic degree.
About Peter Culpepper: Pete Culpepper is the Chief Financial Officer for Provectus Pharmaceuticals.